CDMO Rentschler Biopharma is signalling its intent to cut down cell and gene therapy operations by shutting down its UK manufacturing facility in Stevenage.
The Laupheim, Germany-headquartered company said the move is based on evolving market conditions and client needs, citing the need to prioritise sustainable growth. Rentschler will instead put more resources into biologics.
Go deeper with GlobalData
Rentschler’s Stevenage cell and gene therapy plant made viral vectors for clinical and commercial supply. The site is part of a cell and gene therapy cluster called The Catapult Network built in 2014, and later expanded in 2020. The campus includes a 7,700-metre squared manufacturing facility, a 100-metre squared analytical technologies laboratory, and skills and training laboratories. Rentschler Biopharma stated its UK facility at Stevenage was launched in 2021.
Rentschler also has rented space in the nearby Sycamore House, an office and laboratory space built in May 2023. As of June 2023, Rentschler was a tenant alongside GSK, Achilles Therapeutics, and Immunome, amongst others.
Rentschler employs around 1,400 people across the plants in Massachusetts in the US and Laupheim in Germany, as well as the Stevenage facility.
Rentschler did not immediately respond to Pharmaceutical Technology’s request to disclose the number of employees at the UK site who will be affected by this move. The CDMO also did not immediately reveal future plans for the hub.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataRentschler’s CEO Benedikt von Braunmühl said: “The cell and gene therapy market has experienced slower-than-expected growth, with demand across the industry not meeting our expectations.”
Von Braunmühl added that the company has determined biologics to be an area where it sees greater demand and value growth.
Speaking about those working at the plant, he said, “We are committed to supporting the affected employees by providing resources and assistance during this transition period.”
Unlike the Stevenage plant, Rentschler’s other two sites have benefitted from significant investment over the past year. In October 2024, the company announced plans to upgrade and expand the Laupheim facility. Construction is slated to begin by spring this year and the expansion is expected to be fully operational by 2028. Three months before the Laupheim plans were revealed, the CDMO announced the Massachusetts facility had become fully operational.
Rentschler is not the only company in the pharmaceutical sector that is scaling down operations in the cell and gene therapy sector. In 2022, GSK terminated its T-cell receptor therapy collaboration with Lyell Immunopharma in late 2022. Once a booming field for investment, cell and gene therapies have become tricky to develop, with companies facing manufacturing challenges and scalability hurdles.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
